mozavaptan has been researched along with Polycystic Kidney, Autosomal Dominant in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hammond, S; Meng, X; Mosedale, M; Naisbitt, DJ | 1 |
| 't Hoen, PAC; Charrout, M; Hettne, KM; Kors, JA; Kudrin, R; Malas, TB; Peters, DJM; Roos, M; Starikov, S; van Mulligen, EM; Vlietstra, WJ; Vos, R | 1 |
| de Heer, E; Gansevoort, RT; Meijer, E; Peters, DJ; van Goor, H; Veraar, KA; Versteeg, IB; Zittema, D | 1 |
| de Heer, E; de Jong, PE; de Krey, SR; Gansevoort, RT; Leonhard, WN; Meijer, E; Mulder, GM; Peters, DJ; Struck, J; van den Born, J; van der Wal, AM; van Goor, H | 1 |
| Devuyst, O; Serra, A; Wang, X | 1 |
| Gattone, VH; Harris, PC; Qian, Q; Somlo, S; Torres, VE; Wang, X | 1 |
| Higashihara, E | 1 |
| Torres, VE | 1 |
2 review(s) available for mozavaptan and Polycystic Kidney, Autosomal Dominant
| Article | Year |
|---|---|
[Polycystic kidney disease].
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Calcium Channels; Cell Proliferation; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Polycystic Kidney, Autosomal Dominant; TRPP Cation Channels | 2007 |
Role of vasopressin antagonists.
Topics: Adolescent; Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Fluids; Cell Proliferation; Drug Evaluation, Preclinical; Hormone Antagonists; Humans; Kidney; Male; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan; Treatment Outcome | 2008 |
6 other study(ies) available for mozavaptan and Polycystic Kidney, Autosomal Dominant
| Article | Year |
|---|---|
Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan.
Topics: Antidiuretic Hormone Receptor Antagonists; Clone Cells; Humans; Polycystic Kidney, Autosomal Dominant; T-Lymphocytes; Tolvaptan | 2023 |
Drug prioritization using the semantic properties of a knowledge graph.
Topics: Benzazepines; Clinical Trials as Topic; Databases, Factual; Drug Repositioning; Humans; Information Dissemination; Knowledge; Pattern Recognition, Automated; Polycystic Kidney, Autosomal Dominant; Semantics | 2019 |
Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cysts; Disease Models, Animal; Drinking; Female; Kidney; Male; Mice, Knockout; Organ Size; Polycystic Kidney, Autosomal Dominant; Protein Kinase C; Time Factors; Water | 2016 |
Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Kidney; Male; Mice; Mice, Knockout; Polycystic Kidney, Autosomal Dominant; Protein Kinase C | 2011 |
Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Female; Male; Polycystic Kidney, Autosomal Dominant | 2011 |
Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Mice; Phenotype; Polycystic Kidney, Autosomal Dominant | 2004 |